{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:25:32Z","timestamp":1761920732454,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.msard.2020.102076","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T07:38:02Z","timestamp":1587973082000},"page":"102076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Inclusion of the Symbol Digit Modalities Test in a revised assessment of \u2018no evidence of disease activity-4 (NEDA-4)\u2019 in Latin-American patients with multiple sclerosis"],"prefix":"10.1016","volume":"42","author":[{"given":"Carlos","family":"Guevara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Violeta","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Orellana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Silva-Rosas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth J","family":"Barker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J","family":"Kempton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"de Grazia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2020.102076_bib0001","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00415-007-0599-3","article-title":"Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates","volume":"254","author":"Anderson","year":"2007","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib0002","article-title":"Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian consensus recommendations","volume":"1","author":"Arnold","year":"2015","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.102076_bib0003","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/brain\/awl303","article-title":"Manifestations of early brain recovery associated with abstinence from alcoholism","volume":"130","author":"Bartsch","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102076_bib0004","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/hbm.21344","article-title":"Evaluating and reducing the impact of white matter lesions on brain volume measurements","volume":"33","author":"Battaglini","year":"2012","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.msard.2020.102076_bib0005","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102076_bib0006","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-12-55","article-title":"Brief international cognitive assessment for MS (BICAMS): international standards for validation","volume":"12","author":"Benedict","year":"2012","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib0007","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1212\/NXI.0000000000000271","article-title":"Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS","volume":"3","author":"Bergman","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102076_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2016.12.001","article-title":"No evidence of disease activity (NEDA) in MS should include CSF biology - towards a \u201cDisease-free status score\u201d","author":"Bonnan","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102076_bib0009","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/brain\/122.4.625","article-title":"The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis","volume":"122","author":"Cottrell","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102076_bib0010","article-title":"Multiple sclerosis epidemiology in Latin America: an updated survey","volume":"3","author":"Cristiano","year":"2017","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2020.102076_bib0011","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40263-014-0140-z","article-title":"Clinical relevance of brain volume measures in multiple sclerosis","volume":"28","author":"De Stefano","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2020.102076_bib0012","first-page":"93","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"De Stefano","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2020.102076_bib0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-0404.2011.01571.x","article-title":"Incidence of multiple sclerosis in Chile. A hospital registry study","volume":"125","author":"Diaz","year":"2012","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2020.102076_bib0014","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1212\/01.WNL.0000161871.83614.BB","article-title":"Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects","volume":"64","author":"Enzinger","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102076_bib48","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-019-09272-6","article-title":"Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis","author":"Frau","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib0015","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4067\/S0034-98872014000300001","article-title":"Gene geography of Chile: regional distribution of American, European and African genetic contributions","volume":"142","author":"Fuentes","year":"2014","journal-title":"Rev. Med. Chile"},{"key":"10.1016\/j.msard.2020.102076_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(12)70230-2","article-title":"Measurement and clinical effect of grey matter pathology in multiple sclerosis","author":"Geurts","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13669","article-title":"\u2018No evidence of disease activity\u2019 \u2013 is it an appropriate surrogate in multiple sclerosis?","author":"Hegen","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib0019","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2008.12.005","article-title":"Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study","volume":"282","author":"Horakova","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102076_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.msard.2018.10.020","article-title":"No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany","volume":"27","author":"Huhn","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2020.102076_bib0020","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1177\/1352458518803785","article-title":"Recommendations for cognitive screening and management in multiple sclerosis care","volume":"24","author":"Kalb","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102076_bib0021","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u201cno evidence of disease activity\u201d (NEDA-4) in relapsing-remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102076_bib0022","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2020.102076_bib0023","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hbm.20500","article-title":"Effects of acute dehydration on brain morphology in healthy humans","volume":"30","author":"Kempton","year":"2009","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.msard.2020.102076_bib0024","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/CPJ.0000000000000112","article-title":"Multiple sclerosis in US minority populations: clinical practice insights","volume":"5","author":"Khan","year":"2015","journal-title":"Neurol. Clin. Pract."},{"key":"10.1016\/j.msard.2020.102076_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3988\/jcn.2019.15.1.20","article-title":"Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis","volume":"15","author":"Kim","year":"2019","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib0025","first-page":"1509","article-title":"Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative analysis","volume":"23","author":"MacKenzie","year":"2002","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.msard.2020.102076_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419840593","article-title":"Advances in spinal cord imaging in multiple sclerosis","author":"Moccia","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2020.102076_bib0027","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuroimage.2015.05.077","article-title":"Diurnal fluctuations in brain volume: statistical analyses of MRI from large populations","volume":"118","author":"Nakamura","year":"2015","journal-title":"Neuroimage"},{"key":"10.1016\/j.msard.2020.102076_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135974","article-title":"A longitudinal study of disability, cognition and gray matter atrophy in early multiple sclerosis patients according to evidence of disease activity","volume":"10","author":"Nygaard","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2020.102076_bib50","doi-asserted-by":"crossref","first-page":"1.412","DOI":"10.1212\/WNL.90.15_supplement.P1.412","article-title":"Early disease stage of Multiple Sclerosis in Chilean patients: cognitive impairment is a key domain and does not relate to MRI measures","volume":"90","author":"Oliva","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102076_bib42","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1337-z","article-title":"Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: A prespecified 2-year interim analysis of STRIVE","volume":"19","author":"Perumal","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2020.102076_bib0029","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib49","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1007\/s00415-018-9070-x","article-title":"No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study","volume":"265","author":"Prosperini","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jocn.2018.10.095","article-title":"Brain volume loss and no evidence of disease activity over 3\u202fyears in multiple sclerosis patients under interferon beta 1a subcutaneous treatment","volume":"59","author":"Rojas","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2020.102076_bib0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749802","article-title":"An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM)","volume":"11","author":"Schmidt","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2020.102076_bib0032","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00004728-200105000-00022","article-title":"Normalized accurate measurement of longitudinal brain change","volume":"25","author":"Smith","year":"2001","journal-title":"J. Comput. Assist. Tomogr."},{"key":"10.1016\/j.msard.2020.102076_bib0033","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","article-title":"Accurate, robust, and automated longitudinal and cross-sectional brain change analysis","volume":"17","author":"Smith","year":"2002","journal-title":"Neuroimage"},{"key":"10.1016\/j.msard.2020.102076_bib0034","doi-asserted-by":"crossref","first-page":"007","DOI":"10.1212\/WNL.90.15_supplement.S24.007","article-title":"Including blood neurofilament light chain in the NEDA concept in relapsing\u2013remitting multiple sclerosis trials (S24.007)","volume":"90","author":"Sormani","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102076_bib0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756285614560733","article-title":"Towards the implementation of \u201cno evidence of disease activity\u201d in multiple sclerosis treatment: the multiple sclerosis decision model","volume":"8","author":"Stangel","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2020.102076_bib0036","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1148\/radiol.2018172468","article-title":"Measurement of whole-brain and gray matter atrophy in multiple sclerosis: assessment with MR Imaging","volume":"288","author":"Storelli","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.msard.2020.102076_bib0037","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1177\/1352458518808204","article-title":"Symbol Digit Modalities Test: a valid clinical trial endpoint for measuring cognition in multiple sclerosis","volume":"25","author":"Strober","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2020.102076_bib0038","doi-asserted-by":"crossref","DOI":"10.1038\/nrneurol.2017.171","article-title":"Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting","author":"Tur","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib0039","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/13854046.2016.1184317","article-title":"A new assessment tool for patients with multiple sclerosis from Spanish-speaking countries: validation of the brief international cognitive assessment for MS (BICAMS) in Argentina","volume":"30","author":"Vanotti","year":"2016","journal-title":"Clin. Neuropsychol."},{"key":"10.1016\/j.msard.2020.102076_bib51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2020.102076_bib43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40263-017-0482-4","article-title":"Assessing \u2018No Evidence of Disease Activity\u2019 Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcom","volume":"32","author":"Weinstock-Guttman","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2020.102076_bib45","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10072-018-3487-y","article-title":"Brain volume loss is present in Japanese multiple sclerosis patients with no evidence of disease activity","volume":"39","author":"Yokote","year":"2018","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2020.102076_bib44","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/03007995.2018.1458708","article-title":"No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study","volume":"34","author":"Zivadinov","year":"2018","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820301528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:50:32Z","timestamp":1761900632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820301528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":49,"alternative-id":["S2211034820301528"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102076","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inclusion of the Symbol Digit Modalities Test in a revised assessment of \u2018no evidence of disease activity-4 (NEDA-4)\u2019 in Latin-American patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102076"}}